查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047997

硫酸新黴素市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Neomycin Sulphate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球硫酸新黴素市場預計將從 2025 年的 3.1719 億美元大幅成長至 2031 年的 4.5377 億美元，複合年成長率為 6.15%。

硫酸新黴素是一種Aminoglycosides抗生素，來自弗氏鏈黴菌（Streptomyces fradiae），因其對革蘭氏陰性菌的有效性，被廣泛應用於獸醫和人類醫學領域。該市場的潛在成長主要受全球動物性蛋白質需求不斷成長的驅動，這促使人們需要採取嚴格的疾病控制策略來對抗牲畜和家禽的腸道感染疾病。同時，製藥業也透過生產用於預防人類皮膚感染疾病的外用藥物，為該市場的持續需求做出了貢獻。這些因素構成了集約化畜牧養殖和醫療保健中細菌控制的基本要求，使該市場免受暫時性波動的影響。

市場概覽
預測期 2027-2031
市場規模：2025年 3.1719億美元
市場規模：2031年 4.5377億美元
複合年成長率：2026-2031年 6.15%
成長最快的細分市場 疫苗生產
最大的市場 亞太地區

然而，儘管成長要素強勁，市場仍面臨一個重大障礙：抗菌素抗藥性（AMR）監管力度加大。監管機構正逐步限制關鍵抗生素的預防性使用，直接影響了抗生素的消費。世界動物衛生組織（OIE）的最新數據顯示，2020年至2022年間全球動物抗生素使用量下降了5%，凸顯了抗生素管理措施對產業日益成長的影響，也印證了法規環境的嚴峻性。這些嚴格的法規迫使生產商在複雜的合規框架內運營，這可能會阻礙硫酸新黴素在關鍵農業領域的銷售量成長。

市場促進因素

全球動物保健產業的成長是市場擴張的關鍵驅動力，尤其是在家禽和豬的腸道病原體防治中，藥用飼料添加劑的使用量不斷增加。隨著畜牧養殖戶擴大經營規模以滿足日益成長的動物性蛋白質需求，他們越來越依賴Aminoglycosides抗生素（例如硫酸新黴素）來維持牲畜健康和預防細菌感染。近期消費數據也印證了這一趨勢，儘管存在監管方面的挑戰，但其使用量仍在持續成長。例如，根據美國食品藥物管理局（FDA）於2025年12月發布的《2024年總結報告》，2024年美國國內用於肉類動物的重要抗菌藥物銷售量年增16%。這一銷售量的顯著成長凸顯了市場對有效抗生素治療的持續依賴。此外，Phibro Animal Health Corporation 報告稱，其 2025 會計年度第一季藥用飼料添加劑業務的淨銷售額成長了 81%，這表明動物用藥品行業具有強勁的商業性活力和市場整合趨勢。

同時，由於對局部皮膚製劑的需求不斷成長，市場呈現出強勁的成長勢頭，其中新黴素仍然是治療細菌性皮膚感染疾病和預防術後併發症的關鍵活性成分。受消費者對創傷護理認知的提高以及需要預防性治療的輕微皮膚擦傷發生率上升的推動，製藥公司抗生素乳膏和軟膏的銷售額大幅成長。這項需求反映在主要公司近期的財務表現。根據Haleon plc於2025年2月發布的“2024年全年財務業績”，該公司皮膚健康業務板塊實現了中等個位數的有機銷售成長，這主要得益於其局部抗生素品牌的強勁表現。該板塊的擴張，以及來自獸醫領域的需求，凸顯了人類局部抗生素在整個硫酸新黴素市場中的關鍵作用。

市場挑戰

日益嚴格的抗菌素抗藥性（AMR）法規環境對全球硫酸新黴素市場的需求成長構成了重大限制。監管機構和農業組織正在嚴格執行合理使用政策，限制了關鍵抗菌藥物的預防性使用——而這種做法傳統上佔獸醫領域新黴素消費的大部分。這種從廣泛疾病預防到更具針對性的治療應用的根本性轉變，必然導致市場規模萎縮。因此，隨著生產商採取替代醫療保健措施以遵守這些嚴格的法規，牲畜飼料和飲用水添加劑中對硫酸新黴素的基本需求正面臨持續下降，直接阻礙了整體市場成長。

目前的行業統計數據清楚地顯示了這些合理使用政策對消費的影響。英國家禽協會報告稱，到2025年，英國禽肉產業將全面淘汰預防性抗生素的使用，抗生素總用量將比2012年減少83%以上。這些統計數據表明，遵守抗菌素抗藥性（AMR）法規實際上限制了銷售量成長的潛力，迫使生產商在需求有限的市場中運作。

市場趨勢

創傷護理領域正經歷快速變革，尤其是在慢性糖尿病足潰瘍和嚴重燒傷的治療方面，因為硫酸新黴素已被應用於先進的水凝膠和生物膜膜敷料系統中。製造商正在突破傳統疏水性軟膏的限制（傳統軟膏的滲透性通常有限），開發出能夠持續局部釋放抗生素並有效破壞細菌生物膜的保水水凝膠。這項技術進步直接滿足了複雜難癒合傷口（全身性抗生素療效不佳）中有效控制感染的迫切需求。這些先進配方的商業性可行性也得到了公司近期業績的支持。史密斯醫療（Smith & Nephew）於2025年11月發布的2025年第三季財報顯示，其高階傷口管理業務的核心銷售額成長了6.0%。這主要得益於高級傷口生物活性產品組合的兩位數成長，證實了市場正向高科技治療敷料發生決定性轉變。

同時，市場正經歷著根本性的轉變，從傳統的畜牧業轉向專門針對伴侶動物的耳部和皮膚產品。動物用藥品公司正在拓展產品線，以掌握快速成長的「寵物人性化」趨勢，專注於開發用於治療犬貓皮膚感染疾病的新黴素類藥物，而非利潤微薄的飼料添加劑。這項策略重組的驅動力在於寵物飼主越來越願意投資更優質的皮膚病治療方案。業界領導企業的財務揭露也印證了該領域的顯著成長。碩騰公司於2025年11月發布的2025年第三季財報顯示，其國際伴侶動物產品銷售額成長了8%，主要得益於其皮膚病產品系列的持續需求。這凸顯了寵物護理產業感染疾病控制產品的盈利發展潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球硫​​酸新黴素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 應用領域（皮膚感染疾病、眼部感染疾病、耳部感染疾病、疫苗生產、獸醫學、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美硫酸新黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲硫酸新黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區硫酸新黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲硫酸新黴素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美新黴素硫酸鹽市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球硫​​酸新黴素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Limited
  • Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
  • Myland Pharma Pvt Ltd
  • Xi'an International Healthcare Factory Co., Ltd.
  • Shandong Yifan Chemical Technology Co., Ltd.
  • Xi'an Henrikang Biotech Co., Ltd.
  • Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
  • Jinyao Xinrui Pharmaceutical Co. Ltd
  • Xinyu Pharmaceutical Co. Ltrd
  • Humanwell Healthcare（Group）Co., Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28764

The global Neomycin Sulphate market is projected to expand significantly, rising from USD 317.19 Million in 2025 to USD 453.77 Million by 2031, exhibiting a compound annual growth rate of 6.15%. Neomycin Sulphate, an aminoglycoside antibiotic derived from Streptomyces fradiae, is widely used in both veterinary and human medicine due to its effectiveness against Gram-negative bacteria. This market's fundamental growth is primarily propelled by the increasing worldwide demand for animal protein, which necessitates stringent disease management strategies to combat enteric infections in livestock and poultry. Concurrently, the pharmaceutical industry contributes to sustained demand through the production of topical medications designed to prevent skin infections in humans. These drivers are fundamental requirements for bacterial control in intensive farming and healthcare, distinguishing them from temporary market fluctuations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 317.19 Million
Market Size 2031USD 453.77 Million
CAGR 2026-20316.15%
Fastest Growing SegmentVaccine Production
Largest MarketAsia Pacific

However, despite these robust growth drivers, the market faces a considerable hurdle from the escalating regulatory scrutiny concerning antimicrobial resistance (AMR). Regulatory bodies are progressively curtailing the prophylactic application of vital antibiotics, directly influencing consumption levels. This intensifying regulatory climate is underscored by recent data from the World Organisation for Animal Health, which reported a 5% decline in global antimicrobial use in animals between 2020 and 2022, highlighting the increasing effect of stewardship initiatives on the industry. These stringent regulations oblige manufacturers to operate within intricate compliance frameworks, potentially hindering the growth in sales volume for neomycin sulphate within crucial agricultural sectors.

Market Driver

The growth of the global veterinary healthcare sector serves as a significant impetus for market expansion, especially driven by the increased application of medicated feed additives to manage enteric pathogens in poultry and swine. As livestock producers expand operations to satisfy growing demand for animal protein, their dependence on aminoglycosides such as neomycin sulphate has intensified for maintaining herd health and preventing bacterial outbreaks. Recent consumption data confirms this trend, showing a resurgence in usage despite existing regulatory challenges. For instance, the U.S. FDA's December 2025 '2024 Summary Report' revealed a 16% increase in domestic sales of medically important antimicrobials for food-producing animals in 2024 compared to the previous year. This substantial volume growth highlights the market's ongoing reliance on efficacious antibiotic treatments. Moreover, Phibro Animal Health Corporation reported an 81% surge in net sales for its Medicated Feed Additives segment during the first fiscal quarter of 2025, indicating strong commercial dynamism and market consolidation within the animal health sector.

Concurrently, the market is experiencing significant momentum from the escalating demand for topical dermatological preparations, with neomycin remaining a crucial active ingredient for addressing bacterial skin infections and averting post-surgical complications. Pharmaceutical firms observe consistent sales of antibiotic creams and ointments, propelled by greater consumer understanding of wound care and an increasing occurrence of minor skin abrasions needing preventative treatment. This demand is reflected in the recent financial outcomes of leading consumer health companies. Haleon plc's 'Full Year Results 2024', published in February 2025, indicated high-single-digit organic revenue growth within its Skin Health category, largely attributable to the robust performance of its topical antibiotic brands. The expansion of this segment underscores the vital contribution of human-use topical antibiotics to the overall neomycin sulphate market, supplementing the volume demand originating from the veterinary domain.

Market Challenge

The intensifying regulatory environment surrounding antimicrobial resistance (AMR) presents a significant constraint on the volume expansion potential of the global Neomycin Sulphate market. Regulatory authorities and agricultural alliances are rigorously implementing stewardship policies that restrict the prophylactic use of critically important antibiotics, a practice that traditionally constituted a large share of neomycin consumption within the veterinary sector. This fundamental shift, moving from widespread disease prevention to more focused therapeutic applications, inherently reduces the available market. Consequently, as producers adopt alternative health management approaches to adhere to these strict regulations, the foundational demand for neomycin sulphate in livestock feed and water additives faces a lasting reduction, thereby directly hindering overall market growth.

The effect of these stewardship policies on consumption volumes is clearly demonstrated by current industry statistics. The British Poultry Council reported in 2025 that the UK poultry meat industry has sustained a complete absence of preventative antibiotic use and has collectively reduced total antibiotic usage by more than 83% since 2012. These statistics exemplify how effective adherence to AMR regulations effectively limits the potential for increased sales volumes, compelling manufacturers to operate within a market characterized by restricted demand.

Market Trends

The wound care sector is undergoing rapid transformation with the incorporation of neomycin sulphate into sophisticated hydrogel and biofilm dressing systems, especially for managing chronic diabetic foot ulcers and severe burn injuries. Manufacturers are innovating beyond conventional hydrophobic ointments, which typically exhibit limited penetration, by developing moisture-retentive hydrogels that provide sustained, localized antibiotic release and effectively disrupt bacterial biofilms. This technological progression directly addresses the urgent requirement for efficient infection control in intricate, non-healing wounds where systemic antibiotics prove inadequate. The commercial viability of these advanced formulations is confirmed by recent corporate results. Smith+Nephew's 'Third Quarter 2025 Trading Report' from November 2025 highlighted a 6.0% underlying revenue growth for its Advanced Wound Management unit, predominantly driven by double-digit expansion in its Advanced Wound Bioactives portfolio, thus affirming the market's decisive shift towards high-technology therapeutic dressings.

Concurrently, the market is witnessing a fundamental shift towards specialized otic and dermatological products for companion animals, moving away from its traditional dependence on livestock farming. Veterinary pharmaceutical firms are increasingly broadening their product offerings to leverage the burgeoning 'pet humanization' trend, focusing on developing specific neomycin-based treatments for skin infections in dogs and cats instead of lower-margin feed additives. This strategic realignment is fueled by pet owners' heightened propensity to invest in superior healthcare solutions for dermatological issues. The substantial growth of this sector is supported by financial disclosures from industry leaders. Zoetis Inc.'s 'Third Quarter 2025 Results' from November 2025 reported an 8% increase in revenue for its international companion animal products, largely propelled by sustained demand within its dermatology portfolio, thereby emphasizing the profitable prospects of infection control products within the pet care industry.

Key Market Players

  • Pfizer Limited
  • Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
  • Myland Pharma Pvt Ltd
  • Xi'an International Healthcare Factory Co., Ltd.
  • Shandong Yifan Chemical Technology Co., Ltd.
  • Xi'an Henrikang Biotech Co., Ltd.
  • Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
  • Jinyao Xinrui Pharmaceutical Co. Ltd
  • Xinyu Pharmaceutical Co. Ltrd
  • Humanwell Healthcare (Group) Co., Ltd

Report Scope

In this report, the Global Neomycin Sulphate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neomycin Sulphate Market, By Sales Channel

  • Direct
  • Indirect

Neomycin Sulphate Market, By End Use

  • Skin Infection
  • Eye Infection
  • Ear Infection
  • Vaccine Production
  • Veterinary Medicine
  • Others

Neomycin Sulphate Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neomycin Sulphate Market.

Available Customizations:

Global Neomycin Sulphate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neomycin Sulphate Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Skin Infection, Eye Infection, Ear Infection, Vaccine Production, Veterinary Medicine, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Neomycin Sulphate Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Neomycin Sulphate Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Neomycin Sulphate Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Neomycin Sulphate Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Neomycin Sulphate Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Neomycin Sulphate Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Neomycin Sulphate Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Neomycin Sulphate Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Neomycin Sulphate Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Neomycin Sulphate Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Neomycin Sulphate Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Neomycin Sulphate Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Neomycin Sulphate Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Neomycin Sulphate Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Neomycin Sulphate Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Neomycin Sulphate Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Neomycin Sulphate Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Neomycin Sulphate Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Neomycin Sulphate Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Neomycin Sulphate Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Neomycin Sulphate Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neomycin Sulphate Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Neomycin Sulphate Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Neomycin Sulphate Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Neomycin Sulphate Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Shandong Qilu King-Phar Pharmaceutical Co., Ltd.
  • 15.3. Myland Pharma Pvt Ltd
  • 15.4. Xi'an International Healthcare Factory Co., Ltd.
  • 15.5. Shandong Yifan Chemical Technology Co., Ltd.
  • 15.6. Xi'an Henrikang Biotech Co., Ltd.
  • 15.7. Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
  • 15.8. Jinyao Xinrui Pharmaceutical Co. Ltd
  • 15.9. Xinyu Pharmaceutical Co. Ltrd
  • 15.10. Humanwell Healthcare (Group) Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer